Clinical Study for Xu-Ming-Tong-Mai Decoction in the treatment of Acute Ischemic Stroke

Chongqing Traditional Chinese Medicine Hospital0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•1. All the patients were diagnosed as ischemic stroke by CT or MRI;
•2. The NIHSS scores of patients ranged from 3 to 15(including 3 and 15);
•3. Aged 40 to 80 years;
•4. The patient's onset is less than 72 hours;
•5. The trial was informed consent of the patient or the patient's family or their legal representative and signed the informed consent form.

•1. Patients who have received or are about to undergo endovascular interventional therapy (including arterial thrombolysis, bridging, mechanical thrombectomy, angioplasty and stenting);
•2. Tests confirmed patients with brain trauma, brain tumors, brain parasitosis, and other brain disorders, or with immune system disorders;
•3. The score of the modified Rankin scale (Rankin scale) was more than 2;
•4. Patients with malignant tumor, CACHEXIA, moderate or severe malnutrition (albumin < 25g / L, BMI <17);
•5. Patients with severe hepatic and renal dysfunction (ALT or AST >80 U/L, The male Serum Creatinine >266 umol /L,The female Serum Creatinine >212 Umol/L);
•6. Patients with other effects on limb function and limb function disorders affect the neurological examination;
•7. Other diseases or mental disorders that the researchers believe may limit neurologic assessment or affect patient follow-up;
•8. Pregnant or lactating women;
•9. Patients undergoing clinical trials for other drugs;
•10. Patients with contraindications to the drug therapy used in this study.

发起方

Chongqing Traditional Chinese Medicine Hospital